TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01849822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural Prosthetic System
Description: The Neural Prosthetic System is primarily composed of two NeuroPort Arrays. Each array is comprised of 100 microelectrodes (1.5 mm in length) uniformly organized on a 4 mm x 4 mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Each microelectrode has a platinum tip that is 100-200 microns in length and offers impedance values from 100-800 kilo-ohms. Of the 100 electrodes, 96 are wire bonded using 25 micron gold alloy insulated wires collectively sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the printed circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface.
Study: NCT03445351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic, resistance and concorrent.
Description: All protocols followed the American College of Sports Medicine (ACSM) guidelines , with frequency of three times per week, duration between 40-50 minutes, low to high intensity, modified according to the physical needs of each participant, respecting the physical training principles.
Study: NCT03153137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Description: film-coated tablet; oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: film-coated tablet; oral use
Study: NCT02982733

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ABS
Description: Ankaferd Blood Stopper

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TR Band
Description: Transradial band

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CS
Description: Sterile Gauze
Study: NCT04495803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Group Therapy for Perinatal Anxiety
Description: The treatment consists of cognitive and behavioural strategies for treating anxiety, tailored specifically to a perinatal/postpartum population. Additional strategies for COVID-19 specific worry content have been included.
Study: NCT02501538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous O2 device
Description: A portable device that delivers continuous diffusion of oxygen.
Study: NCT01116986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long Term Nicotine Patch+ Nicotine Gum During Quit Attempt
Description: If randomized to this condition:~After the target quit day:~Patch:~IF \> 10 cigs/day: one 21 mg nicotine patch per day for 12 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.~IF \< or = 10 cigs/day: one 14 mg nicotine patch per day for 12 weeks, then one 7 mg for 4 weeks.~Gum:~IF \> 24 cigs/day: ten 4 mg nicotine gum per day for 16 weeks. IF \< or = 24 cigs/day: ten 2 mg nicotine patch per day for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long Term Nicotine Patch+ Nicotine Gum During Quit Attempt
Description: If randomized to this condition:~After the target quit day:~Patch:~IF \> 10 cigs/day: one 21 mg nicotine patch per day for 12 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.~IF \< or = 10 cigs/day: one 14 mg nicotine patch per day for 12 weeks, then one 7 mg for 4 weeks.~Gum:~IF \> 24 cigs/day: ten 4 mg nicotine gum per day for 16 weeks. IF \< or = 24 cigs/day: ten 2 mg nicotine patch per day for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long Term Nicotine Patch+ Nicotine Gum During Quit Attempt
Description: If randomized to this condition:~After the target quit day:~Patch:~IF \> 10 cigs/day: one 21 mg nicotine patch per day for 12 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.~IF \< or = 10 cigs/day: one 14 mg nicotine patch per day for 12 weeks, then one 7 mg for 4 weeks.~Gum:~IF \> 24 cigs/day: ten 4 mg nicotine gum per day for 16 weeks. IF \< or = 24 cigs/day: ten 2 mg nicotine patch per day for 16 weeks.
Study: NCT03812497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Education Program
Description: The every participants will have individualized education program about a way of dietary control and exercise in their usual life.
Study: NCT00669799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gentamyacin
Description: topical internasal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gentamyacin
Description: intranasal
Study: NCT00592085

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Participants will use a computer to complete a series of questionnaires.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Participants will use a computer to complete a series of questionnaires.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Relapse Prevention Counseling
Description: Total of 6 counseling calls for Smoking Relapse: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relapse Plus Alcohol Risk Reduction Counseling
Description: Total of 6 counseling calls for both Smoking Relapse and Alcohol Risk: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
Study: NCT02260882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOVAX™ 23
Description: PNEUMOVAX™ 23 (23-Valent Pneumococcal Polysaccharide Vaccination, V110, PPV23)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOVAX™ 23
Description: PNEUMOVAX™ 23 (23-Valent Pneumococcal Polysaccharide Vaccination, V110, PPV23)
Study: NCT00959166

Intervention type: OTHER
Group type: OTHER
Intervention: PET scan
Description: PET brain scan

Intervention type: OTHER
Group type: OTHER
Intervention: PET scan
Description: PET brain scan
Study: NCT02745392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP-Zolmitriptan
Description: ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP-Zolmitriptan
Description: ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP-Zolmitriptan
Description: ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch(es) to match ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system (one or two patches)
Study: NCT00426153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Participants received Octreotide LAR® Depot injections (up to 40 mg)intramuscularly every 28 days (+/- 5 days) for one year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year
Study: NCT03507790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT1812
Description: Active Study Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT1812
Description: Active Study Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active study drug
Study: NCT00615836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin Melt
Description: An orally disintegrating tablet of desmopressin administered under the tongue (sublingually), without water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin Melt
Description: An orally disintegrating tablet of desmopressin administered under the tongue (sublingually), without water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin Melt
Description: An orally disintegrating tablet of desmopressin administered under the tongue (sublingually), without water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin Melt
Description: An orally disintegrating tablet of desmopressin administered under the tongue (sublingually), without water.
Study: NCT05138367

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplantation of human UCA-PSCs or WJ-MSCs into ovaries of POF patients
Description: After vaginal sterilization, TVUS-guided transplantation was performed by the senior-level medical physician B Wang), using a SIEMENS ACUSON ANTANES premium edition system (SIEMENS AG Healthcae Sector, Erlangen, Germany), equipped with a 6-10 MHz probe. The solution (a total number of 2×10\^7cells, 1×10\^7 /400 μL for unilateral ovarian injection) was injected into the ovary by using 21G PTC needles (Hakko Medical Co, Japan) under TVUS guiance. Each patent received up to three transplantations.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplantation of human UCA-PSCs or WJ-MSCs into ovaries of POF patients
Description: After vaginal sterilization, TVUS-guided transplantation was performed by the senior-level medical physician B Wang), using a SIEMENS ACUSON ANTANES premium edition system (SIEMENS AG Healthcae Sector, Erlangen, Germany), equipped with a 6-10 MHz probe. The solution (a total number of 2×10\^7cells, 1×10\^7 /400 μL for unilateral ovarian injection) was injected into the ovary by using 21G PTC needles (Hakko Medical Co, Japan) under TVUS guiance. Each patent received up to three transplantations.
Study: NCT02770573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cavex Bite&White ExSense
Description: a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kuraray Teethmate™ Desensitizer
Description: Calcium-Phosphate-based powder and a liquid mainly water-based.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ghimas Dentin Desensitizer
Description: a fluid desensitizing gel with 30% of nano-hydroxyapatite, added to 70:100 thousandths of micron-sized crystals of nano- hydroxyapatite.
Study: NCT01196273

Intervention type: OTHER
Intervention: Comprehensive non invasive cardiovascular examination
Description: The examination includes:~* Anamnesis incl. admission form~* Physical examination~* Documentation of the medical therapy (incl. HAART)~* Electrocardiogram~* Transthoracic echocardiography~* Exercise electrocardiogram~* 6 minute walk test~* Blood collection~* Questionnaire to quality of life and health economics
Study: NCT03626519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test with Menthol
Description: patients will perform a Six-minute walk test according to American Thoracic Society guidelines

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Test with placebo
Description: patients will perform a Six-minute walk test according to American Thoracic Society guidelines
Study: NCT02550665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Description: using different titration method for the first 4 weeks, and after the 4 weeks, 23mg/day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Description: using different titration method for the first 4 weeks, and after the 4 weeks, 23mg/day orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: using different titration method for the first 4 weeks, and after the 4 weeks, 23mg/day orally
Study: NCT03614910

Intervention type: DEVICE
Intervention: Nanoknife Irreversible Electroporation
Description: Irreversible electroporation will be delivered between electrodes that are placed by intraoperative ultrasound guidance around the tumor
Study: NCT02159430

Intervention type: OTHER
Intervention: Clinical and psychopathological assessment of HAE patients
Study: NCT03049176

Intervention type: DRUG
Intervention: PrEP (Truvada)
Description: oral, daily Truvada for HIV-negative participants

Intervention type: DRUG
Intervention: PrEP (Truvada)
Description: oral, daily Truvada for HIV-negative participants
Study: NCT04199806

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire review
Description: Review data from questionnaires received about MMS experience.
Study: NCT03469414

Intervention type: OTHER
Intervention: Life Space Assessment Scale
Description: This nine question survey asks participants where they have gone in the last week, frequency of those visits, and how independently they went there.

Intervention type: OTHER
Intervention: Life Space Assessment Scale
Description: This nine question survey asks participants where they have gone in the last week, frequency of those visits, and how independently they went there.

Intervention type: OTHER
Intervention: 6-Minute Push Test
Description: The 6 Minute Push Test is a measure of endurance, and requires that the participant wheel themselves around two pylons that are located 15 meters apart for 6 minutes.

Intervention type: OTHER
Intervention: 6-Minute Push Test
Description: The 6 Minute Push Test is a measure of endurance, and requires that the participant wheel themselves around two pylons that are located 15 meters apart for 6 minutes.

Intervention type: OTHER
Intervention: Forward Push Test
Description: This measure of wheelchair propulsion speed asks patients to propel themselves as fast as they can over 20 meters. This task is performed twice, and the average time is used for the score.

Intervention type: OTHER
Intervention: Forward Push Test
Description: This measure of wheelchair propulsion speed asks patients to propel themselves as fast as they can over 20 meters. This task is performed twice, and the average time is used for the score.

Intervention type: OTHER
Intervention: Wheelchair Slalom Test
Description: In this measure, participants propel themselves through an 18 meter slalom course at their maximum self-selected speed, wheeling around seven cones, separated by three, two, or one meter.

Intervention type: OTHER
Intervention: Wheelchair Slalom Test
Description: In this measure, participants propel themselves through an 18 meter slalom course at their maximum self-selected speed, wheeling around seven cones, separated by three, two, or one meter.
Study: NCT03049176

Intervention type: DRUG
Intervention: Antiretrovirals
Description: oral daily antiretrovirals and frequent viral load monitoring for HIV-positive participant

Intervention type: DRUG
Intervention: Antiretrovirals
Description: oral daily antiretrovirals and frequent viral load monitoring for HIV-positive participant

Intervention type: PROCEDURE
Intervention: Semen washing
Description: collection of semen from an HIV-positive man, processing semen to remove HIV, followed by intrauterine insemination

Intervention type: PROCEDURE
Intervention: Artificial vaginal insemination
Description: collection of semen from an HIV-negative man, followed by intravaginal insemination
Study: NCT00866723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study: NCT03369561

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum urea and creatinine and the calculated e GFR
Description: The primary outcome will be AKI during the 1st 7 days of ICU care, as defined by an increase of ≥ 0.3 mg/dl in serum creatinine within 48 hours of ICU admission, an increase of ≥ 50% within 7 days of ICU admission, or acute dialysis
Study: NCT02066285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Study: NCT02361151

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TECH
Description: Weekly newsletter with health information, mobile apps, and self-monitoring materials

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TECH+
Description: Weekly newsletter with health information, mobile apps, and self-monitoring materials along with theory-based mobile web intervention
Study: NCT01210066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: IV fentanyl 1mcg/kg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold pressor test
Description: Non-dominant arm submerged in ice water (0 degrees Celsius) until it is no longer tolerable but less than 5 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl plus cold pressor test
Description: fentanyl IV 1mcg/kg fifteen minutes prior to cold pressor test (arm submerged in ice water until no longer tolerable but no longer than 5 minutes)
Study: NCT02107053

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PJ

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PJ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV iron
Description: IV iron is routinely administered to dialysis patients worldwide to correct anemia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV iron
Description: IV iron is routinely administered to dialysis patients worldwide to correct anemia
Study: NCT04182594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Treatment will start with two injections of 120 mg each followed by maintenance of a single injection of 80 mg administered every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist
Description: GnRH agonist at the discretion of the treating Urologist/Oncologist for 1 year
Study: NCT03169322

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP
Description: patients having chronic periodontitis with mouth breathing habit will receive scaling and root planing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP
Description: patients having chronic periodontitis with mouth breathing habit will receive scaling and root planing
Study: NCT03601988

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent chemo-radiotherapy
Description: Experimental group receive 6 cycles of XELOX chemotherapy and concurrent chemo-radiotherapy. The radiotherapy dose of 45Gy in 25 fractions delivered by IMRT Radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy group receive 8 cycles of XELOX.
Study: NCT05031208

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Memory task
Description: Word recognition task

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Memory task
Description: Word recognition task

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Memory task
Description: Word recognition task
Study: NCT03267160

Intervention type: DIAGNOSTIC_TEST
Intervention: Hemodynamic parameters
Description: Pulse contour cardiac output monitored heart contractility, end-diastolic volume parameters, and lung water parameters.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hemodynamic parameters
Description: Pulse contour cardiac output monitored heart contractility, end-diastolic volume parameters, and lung water parameters.
Study: NCT01174654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: A 12-week contingency management intervention
Study: NCT04421521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture with disposable needles will be implemented
Study: NCT06191770

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Morphine,
Description: Nalbuphine along multimodal analgesia(Paracetamol and Ketamine)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Morphine,
Description: Nalbuphine along multimodal analgesia(Paracetamol and Ketamine)
Study: NCT02800239

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Intake
Description: Amino acid intakes will be varied at 0.2-2.67 g/kg/d
Study: NCT01871311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib + Cetuximab
Description: Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly~Three dose levels for nilotinib:~Dose level -1 200-mg daily Dose level 1 200-mg BID Dose level 2 300-mg BID~Cycle duration will be 4 weeks, with weekly evaluation of toxicity. Assessment of tumor progression will occur every 2 cycles. Subjects will be treated until disease progression or cessation due to intolerable toxicity.
Study: NCT02541760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monteleukast
Description: 4 ml monteleukast daily for one month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone
Description: Inhaled mometasone 1 puff in each side of nose for one month
Study: NCT03045601

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT-FFR
Description: Invasive FFR and CCTA With CT-FFR

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Stress echocardiography
Description: Stress echocardiography and invasive FFR
Study: NCT02349360

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: L. johnsonii N6.2
Description: L. johnsonii N6.2 10\^10 CFU in capsule form administered for 8 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated starch placebo administered for 8 weeks
Study: NCT00921960

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention Care
Description: Intervention Care is defined as a collaborative cardiovascular management between primary care and specialist hospital based services. This will involve natriuretic peptide guided evaluation of LVD and follow-up as appropriate - for example including echocardiographic assessment of left ventricular systolic dysfunction and appropriate pharmacotherapy.